Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double blind, phase 3 trial. Lancet 2014; 384: 319-328.
Published: 5th February 2015
Authors: Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L et al. et al.
Conclusion
In this multicentre trial that included 417 patients, sorafenib increased the median progression-free survival from 5.8 to 10.8 months (hazard ratio 0.59, 95 per cent confidence interval 0.45 to 0.76, P<0.0001).
Pubmed LinkYou may also be interested in
Scientific Surgery
Authors: Cremades M, Ferret G, Pares D, Navines J, Espin F, Pardo F et al.
Scientific Surgery
Authors: Liao M-T, Lee C-P, Lin T-T, Jong C-B, Chen T-Y, Lin L et al.
Scientific Surgery
Authors: Dummer R, Hauschild A, Santinami M, Atkinson V, Mandala M, Kirkwood JM et al.
Scientific Surgery
Authors: Sippel RS, Robbins SE, Poehls JL, Pitt SC, Chen H, Leverson G et al.
Scientific Surgery
Authors: Watson DI, Thompson SK, Devitt PG, Aly A, Irvine T, Woods SD et al.
Scientific Surgery
Authors: Bulger E, May K, Robinson BR, Evans DC, Henry S, Green J et al.
Scientific Surgery
Authors: Lookstein RA, Haruguchi H, Ouriel K, Weidenberg I, Lei L, Cihlar S et al.
Scientific Surgery
Authors: Zwanenburg P, Tol BT, Obdeijn MC, Lapid O, Gans SL, Boermeester MA et al.
Scientific Surgery
Authors: Strobel R, Leonhardt M, Krochmann A, Neumann K, Speichinger F, Hartmann L et al.
Scientific Surgery
Authors: Ruiz-Tovar J, Llavero C, Jimenez-Fuertes M, Duran M, Perez-Lopez M, Garcia-Marin A et al.
Scientific Surgery
Authors: Lima HVG, Rassian R, Novo FCF, Bernini CO, Montero EFS, Utiyama EM et al.
Scientific Surgery
Authors: Turan A, Essber H, Saasouh W, Hovsepyan K, Makarova I, Ayad S et al.